Rapamycin Shows Promise for Extending Human Health Span in Landmark Trial
Summary
A 12-month randomized controlled trial of 200 healthy adults aged 55–75 demonstrated that low-dose rapamycin significantly improved immune function, reduced systemic inflammation, and slowed epigenetic aging by roughly 2.5 years compared to a placebo. These dose-dependent benefits persisted for six months post-treatment, highlighting rapamycin's potential to extend human health span.
Why This Is Interesting
This is the largest and longest human trial of rapamycin specifically designed to measure health span outcomes rather than disease endpoints. Previous studies were smaller and shorter. The 2.5-year epigenetic age reversal effect is striking and the fact that benefits persisted after stopping the drug suggests fundamental biological changes rather than mere symptom suppression.
Published in Nature Aging
"Rapamycin Shows Promise for Extending Human Health Span in Landmark Trial." Nature Aging, 15 Mar. 2026, pubmed.ncbi.nlm.nih.gov/example1/.